ELRIG Drug Discovery

Starts in

October 19, 2021

Liverpool

ELRIG Liverpool

 

Attendance:

In person

Date:

19 - 20 October 2021

Time:

View program

Registration:

Open

Price:

Free

 

We are sponsors at this event!

 

Join Europe’s largest meeting for life sciences industry professionals, to celebrate the innovation and industry and scientific successes.  You will be able to discuss the process of drug discovery and explore efficiency, automation, and remote operation in two session tracks of screening and chemistry, with insights from innovation and disruptive strategies.

 

19th October | bit.bio talk

11.30am-12pm

Listen to our 30 minute track presentation Alzheimer’s Research UK track with our speakers:

'Coding cells for health: Building translational disease models for drug discovery and therapeutics'
Dr Marta Rucka | Product Manager | bit.bio and Dr Sara Gomes | Scientist | bit.bio

20th October | bit.bio workshop

10.50am-12pm 

Join our workshop 'The challenges of cell models: Novel approaches and tools for basic research and drug discovery' with speakers:

'High throughput screening using stem cell derived neurons'
Dr Luckshman Jeremy Anton | Scientist |  Charles River Laboratories
  • Drug discovery for neurodegenerative diseases are often limited by the inability to source cell lines that correctly exhibit disease phenotype in an endogenous manner.
  • Stem cells are able to provide disease relevant models for testing that are scalable and can be differentiated into the appropriate tissue type.
  • Direct reprogramming of stem cells may allow for faster, more efficient differentiation and shows increased robustness in HTS assays compared to traditional differentiation techniques.
'Using iPSC-derived cells to explore mitochondrial disease'
Professor Michael Duchen | Professor of Physiology | University College London
  • Diseases caused by mutations of mitochondrial DNA (mtDNA) are devastating multisystem disorders with highly variable presentations. They are very poorly understood and no disease modifying treatments are available.
  • Because we can’t manipulate the mitochondrial genome, we can’t readily generate animal or cell based models and so these diseases have been very hard to study.
  • We are using iPSC’s derived from patient fibroblasts, differentiated into neurons and muscle to study the pathophysiology in the cells most severely affected by the disease, with the ultimate goal of identifying novel therapeutic targets for these otherwise intractable diseases. Use of stem cell technology has the potential to transform our understanding of these hitherto obscure and difficult diseases.
'Printing synthetic, living and hybrid materials'
Professor Hagan Bayley | Professor of Chemical Biology | University of Oxford
  • By 3D printing, we have assembled functional synthetic tissues comprising patterned networks of thousands of aqueous droplets joined by lipid bilayers.
  • A related printing technology has been used to pattern a variety of living cells, providing structures that include small tumours and neural tissues.
  • Millimeter-scale printed structures can be used as building blocks for cm-scale structures ranging from synthetic axons to hybrid constructs containing both synthetic and living cells.

 

Don't forget to visit our booth B16/B9. We would love to meet you for a chat. You can also view our poster on 'Reprogramming cell identity: enabling the next generation of human cells' at number 40 in the poster gallery.